Experimental combo aims to boost leukemia remission

NCT ID NCT05558124

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing the safety of combining two drugs—Vyxeos and gemtuzumab ozogamicin—for adults newly diagnosed with acute myeloid leukemia. Researchers want to find the best dose that doesn't cause severe side effects. The study will also look at how many patients achieve complete remission. Only 18 people aged 18 to 70 are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vyxeos (a chemotherapy drug combo) and gemtuzumab ozogamicin (a targeted antibody-drug)
What this could lead to: If it works, this could point toward a more effective treatment for newly diagnosed acute myeloid leukemia.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants. The main goal is safety, not proof of effectiveness. Side effects from the chemotherapy combination could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.